Methods and compositions for combination immunotherapy
Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.
1. A method for treating cancer, the method comprising administering to a subject in need thereof:
a) from 1×10 9 to 5×10 11 recombinant, replication-defective adenoviral vectors, each comprising a nucleotide sequence encoding a CEA antigen having at least 90% sequence identity to SEQ ID NO:23, wherein the CEA antigen comprises SEQ ID NO:10 at positions 605-613 of SEQ ID NO:23;
b) avelumab; and
c) a chemotherapy.
2. The method of claim 1 , wherein the avelumab is administered every two weeks.
3. The method of claim 1 , wherein the nucleotide sequence is SEQ ID NO:12.
4. The method of claim 1 , wherein the recombinant replication-defective adenoviral vector comprises a deletion in an E1 gene region and a deletion in an E2b gene region.
5. The method of claim 4 , wherein the replication defective vector is a replication defective adenovirus 5 vector.
6. The method of claim 1 , wherein the recombinant viral vector comprises a deletion in an E2b gene region, an E1 gene region, an E3 gene region, an E4 gene region, or any combination thereof.
7. The method of claim 2 , wherein the chemotherapy comprises cisplatin, leucovorin, fluorouracil, oxaliplatin, or any combination thereof.
8. The method of claim 7 , wherein the chemotherapy comprises leucovorin, fluorouracil, and oxaliplatin.
9. The method of claim 1 , further comprising administering an anti-VEGF antibody.
10. The method of claim 9 , wherein the anti-VEGF antibody is bevacizumab.
11. The method of claim 1 , further comprising administering a vector comprising a nucleic acid sequence encoding a costimulatory molecule.
12. The method of claim 11 , wherein the costimulatory molecule comprises B7, ICAM-1, LFA-3, or any combination thereof.
13. The method of claim 1 , wherein the administering comprises administering 5×10 11 virus particles (VPs) of the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen.
14. The method of claim 1 , wherein the administering comprises administering the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen every two weeks, every three weeks, every four weeks, or every 12 weeks.
15. The method of claim 1 , wherein the administering comprises intravenously, subcutaneously, intramuscularly, or intradermally administering the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen.
16. The method of claim 1 , wherein the subject has cancer of the colon, rectum, breast, lung, pancreas, prostate, gastrointestinal tract, ovary, cervix, head and neck, or any combination thereof.
17. The method of claim 1 , wherein the subject is a human.
18. The method of claim 1 , wherein the subject has a neutralizing antibody against adenovirus.
19. The method of claim 1 , wherein the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen is administered on week 1, 2, 3, 5, 7, and 9.
20. The method of claim 19 , further comprising administering the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen every 6 weeks after the 9th week.
21. The method of claim 1 , wherein the avelumab and the chemotherapy are administered once per week.
22. The method of claim 1 , wherein the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen is administered prior to administration of the avelumab.
23. The method of claim 1 , wherein the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen and the avelumab are administered prior to administration of the chemotherapy and bevacizumab.
24. The method of claim 10 , wherein the recombinant viral vector comprising the nucleotide sequence encoding the CEA antigen and the avelumab are administered concurrently with the administering of the chemotherapy and the bevacizumab.
25. The method of claim 1 , wherein the chemotherapy comprises taxol or a taxol-derivative.